Insulin

Metabolic·MeSH: Insulin Resistance

Prevalence

0.5 / 100K

20 drugs in development·9 companies·1 clinical trial

Drug Pipeline by Phase

Approved(5)

Drug	Company
Humalog® (and Humalog variants)	ELI LILLY & Co (LLY)
Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500	ELI LILLY & Co (LLY)
kirsty	Bone Biologics Corp (BBLG)
semglee	Mylan II B.V. (MYL)
v-go	MANNKIND CORP (MNKD)

Phase 3(2)

Drug	Company
avexitide	Eiger BioPharmaceuticals, Inc. (EIGR)
ersodetug	Rezolute, Inc. (RZLT)

Phase 2(4)

Preclinical(1)

Drug	Company
diabetes therapy	PharmaCyte Biotech, Inc. (PMCB)

Unknown(4)

Drug	Company
AMP-005	Amphastar Pharmaceuticals, Inc. (AMPH)
AMP-025	Amphastar Pharmaceuticals, Inc. (AMPH)
iPScelz™ (iPSC program)	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
Recombinant Human Insulin (AMP-005)	Amphastar Pharmaceuticals, Inc. (AMPH)

Phase 2/Phase 3(4)

Drug	Company
AMP-004	Amphastar Pharmaceuticals, Inc. (AMPH)
AMP-004m	Amphastar Pharmaceuticals, Inc. (AMPH)
Insulin Aspart (AMP-004)	Amphastar Pharmaceuticals, Inc. (AMPH)
Unnamed biosimilar insulin candidate (on file with FDA)	Amphastar Pharmaceuticals, Inc. (AMPH)

BioSniper tracks 20 drugs in development for Insulin across 9 companies.

There are 1 clinical trial targeting Insulin tracked by BioSniper.

The estimated prevalence of Insulin is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.